BG65418B1 - Кит за парентерално приложение на стабилни течни интерферонови състави - Google Patents

Кит за парентерално приложение на стабилни течни интерферонови състави Download PDF

Info

Publication number
BG65418B1
BG65418B1 BG109523A BG10952399A BG65418B1 BG 65418 B1 BG65418 B1 BG 65418B1 BG 109523 A BG109523 A BG 109523A BG 10952399 A BG10952399 A BG 10952399A BG 65418 B1 BG65418 B1 BG 65418B1
Authority
BG
Bulgaria
Prior art keywords
interferon
liquid
kit
administration
parenteral administration
Prior art date
Application number
BG109523A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG109523A (en
Inventor
Mary Dibiasi
Mark Staples
Wen-Li Chung
Eric Scharin
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21875893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG65418(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Publication of BG109523A publication Critical patent/BG109523A/en
Publication of BG65418B1 publication Critical patent/BG65418B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BG109523A 1996-12-24 1999-07-19 Кит за парентерално приложение на стабилни течни интерферонови състави BG65418B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3435396P 1996-12-24 1996-12-24

Publications (2)

Publication Number Publication Date
BG109523A BG109523A (en) 2007-05-31
BG65418B1 true BG65418B1 (bg) 2008-07-31

Family

ID=21875893

Family Applications (2)

Application Number Title Priority Date Filing Date
BG103594A BG65171B1 (bg) 1996-12-24 1999-07-19 Стабилни течни интерферонови състави и метод за стабилизирането им
BG109523A BG65418B1 (bg) 1996-12-24 1999-07-19 Кит за парентерално приложение на стабилни течни интерферонови състави

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BG103594A BG65171B1 (bg) 1996-12-24 1999-07-19 Стабилни течни интерферонови състави и метод за стабилизирането им

Country Status (27)

Country Link
EP (1) EP0948358B2 (enExample)
JP (5) JP4878664B2 (enExample)
KR (2) KR101042660B1 (enExample)
CN (2) CN1222315C (enExample)
AT (1) ATE270899T1 (enExample)
AU (1) AU738362B2 (enExample)
BG (2) BG65171B1 (enExample)
BR (1) BR9714434A (enExample)
CA (1) CA2275890C (enExample)
CZ (1) CZ300636B6 (enExample)
DE (1) DE69729880T3 (enExample)
DK (1) DK0948358T4 (enExample)
EA (1) EA002754B1 (enExample)
EE (2) EE04223B1 (enExample)
ES (1) ES2224290T5 (enExample)
HU (1) HU224222B1 (enExample)
IL (1) IL130524A (enExample)
IS (1) IS2070B (enExample)
MX (1) MX337876B (enExample)
NO (1) NO327844B1 (enExample)
NZ (2) NZ336548A (enExample)
PL (1) PL193447B1 (enExample)
PT (1) PT948358E (enExample)
SI (1) SI0948358T2 (enExample)
SK (1) SK284989B6 (enExample)
TR (1) TR199901968T2 (enExample)
WO (1) WO1998028007A1 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
BR9714434A (pt) * 1996-12-24 2000-05-02 Biogen Inc Formulações de interferon liquidas estáveis
ES2223017T5 (es) * 1997-09-23 2010-10-15 Rentschler Biotechnologie Gmbh Formulaciones liquidas de un interferon beta.
EP1180368B1 (en) * 1999-05-31 2007-04-18 Mitsubishi Chemical Corporation Freeze dried hgf preparations
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
UY27373A1 (es) * 2001-07-09 2003-02-28 Schering Ag Formulaciones de interferón beta-humano
CA2470511C (en) 2001-12-21 2014-05-27 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
JP4340540B2 (ja) * 2002-01-18 2009-10-07 旭化成ファーマ株式会社 可溶性トロンボモジュリン高濃度含有製剤
CN1671410B (zh) 2002-06-21 2010-05-12 诺和诺德医疗保健公司 因子ⅶ多肽的稳定化固体组合物
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
BRPI0409936A (pt) 2003-05-23 2006-04-25 Novo Nordisk Healthcare Ag uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico
CN1318087C (zh) * 2003-06-06 2007-05-30 北京三诺佳邑生物技术有限责任公司 去白蛋白神经生长因子制剂
MXPA06001698A (es) 2003-08-14 2006-05-19 Novo Nordisk Healthcare Ag Composicion farmaceutica liquida y acuosa de polipetidos de factor vii.
CN100548228C (zh) * 2003-11-13 2009-10-14 阿尔扎公司 用于透皮递送的组合物和装置
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
WO2005058283A2 (en) 2003-12-19 2005-06-30 Novo Nordisk Health Care Ag Stabilised compositions of factor vii polypeptides
ZA200610041B (en) * 2004-06-01 2008-07-30 Ares Trading Sa Method of stabilizing proteins
CA2576473C (en) * 2004-08-24 2015-06-30 Daiichi Asubio Pharma Co., Ltd. Liquid preparation of physiologically active peptide
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
ATE415421T1 (de) * 2004-11-10 2008-12-15 Novartis Vaccines & Diagnostic Deamidiertes interferon-beta
CN101102739B (zh) 2005-01-12 2017-02-08 比奥根Ma公司 运输干扰素‑β的方法
CA2593112A1 (en) * 2005-01-21 2006-07-27 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion
ATE501248T1 (de) 2005-07-02 2011-03-15 Arecor Ltd Stabile wässrige systeme mit proteinen
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
JP5323684B2 (ja) 2006-05-04 2013-10-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 多形体
CA3123813C (en) * 2007-12-04 2024-10-08 Remedy Pharmaceuticals, Inc. IMPROVED GLIBENCLAMIDE FORMULATIONS AND RELATED FREEZE-DRYING METHODS, AND FREEZE-DRY SATE PRODUCED THUS
KR20100099298A (ko) 2007-12-20 2010-09-10 메르크 세로노 에스. 에이. Ｐｅｇ­인터페론­베타 제형
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2457590B1 (en) 2008-05-01 2014-12-24 Arecor Limited Protein formulation
EP2328607A1 (en) 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
DE102008051574A1 (de) 2008-10-14 2010-04-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Herstellung von Interferon-beta und deren Varianten
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
TWI508965B (zh) 2008-12-23 2015-11-21 Boehringer Ingelheim Int 有機化合物的鹽形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
DE102009032179A1 (de) 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
KR20190071840A (ko) 2009-11-27 2019-06-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
JP6078344B2 (ja) 2010-02-04 2017-02-08 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト 免疫グロブリン製剤
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
DE102010011430A1 (de) * 2010-03-15 2011-09-15 Kurt Koch Verfahren für den Bau des Nullenergiehauses in Schalenbauweise durch Ausschäumen aller Wände, Decken und Bedachung
MX366325B (es) 2010-05-05 2019-07-05 Boehringer Ingelheim Int Terapia de combinacion.
CA2803504C (en) 2010-06-24 2022-08-30 Boehringer Ingelheim International Gmbh A combination for diabetes therapy comprising linagliptin and a long-acting insulin
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
ES2627409T3 (es) * 2010-12-09 2017-07-28 Maruishi Pharmaceutical Co., Ltd. Estabilizador del acetaminofeno
DK2686002T3 (en) 2011-03-15 2018-04-30 Biogen Ma Inc PROCEDURE FOR REDUCING INFLUENZA-SIMILAR SYMPTOMS CONNECTED WITH INTRAMUSCULAR ADMINISTRATION OF INTERFERON USING AN INCREASING TITRATION DOSAGE REGULATION
KR101985384B1 (ko) 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
CA2864740A1 (en) * 2012-04-19 2013-10-24 C.R. Bard, Inc. Infusates with enhanced ph stability under ethylene oxide sterilization
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ITMI20120913A1 (it) 2012-05-28 2013-11-29 Nicoletta Maxia Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura
CN103143000B (zh) * 2013-03-07 2014-11-05 安徽安科生物工程（集团）股份有限公司 一种重组人干扰素α2b制剂
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
JP2014208669A (ja) * 2014-06-17 2014-11-06 株式会社スリー・ディー・マトリックス タンパク質の凝集抑制剤
EP3226895B1 (en) 2014-12-03 2020-07-22 CSL Behring AG Pharmaceutical product with increased stability comprising immunoglobulins
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
KR101943160B1 (ko) * 2016-10-06 2019-01-30 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
MA49947B1 (fr) 2017-08-22 2023-03-31 Biogen Ma Inc Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
KR102731889B1 (ko) * 2019-07-18 2024-11-19 에이비온 주식회사 2당화된 인터페론-베타 단백질의 정제 방법
CN110714051B (zh) * 2019-11-20 2023-04-07 迈克生物股份有限公司 蛋白c活性测定试剂盒
CN115989239A (zh) * 2020-04-29 2023-04-18 瑷备恩有限公司 具有双重突变的人干扰素β变体和用于改善人干扰素β变体的稳定性的方法
KR20230164127A (ko) * 2021-03-30 2023-12-01 쇼트 파마 슈바이츠 아게 의약품 조성물의 저온 저장용 시스템, 액체 조성물, 방법 및 용도
CN114177273B (zh) * 2021-11-29 2024-05-28 苏州人本药业有限公司 一种含有神经毒素的液体制剂及其制备方法
EP4456900A4 (en) * 2021-12-27 2025-12-24 Enalare Therapeutics Inc RESPIRATORY STIMULATING PARENTERAL FORMULATIONS

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57175125A (en) * 1981-04-20 1982-10-28 Wakunaga Yakuhin Kk Preparation of beta-interferon
EP0082481B2 (en) * 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
JPS60243028A (ja) * 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd インタ−フエロンの可溶化方法
JPS63196268A (ja) * 1987-02-10 1988-08-15 Kanegafuchi Chem Ind Co Ltd 無血清培地で継代増殖可能な形質転換細胞、その育種方法およびその細胞による蛋白質の生産方法
EP0284249A1 (en) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
US4895716A (en) * 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
JPH02124832A (ja) * 1988-07-08 1990-05-14 Toray Ind Inc インターヘェロンβ組成物
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid compositions of gamma interferon
TW249202B (enExample) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
IL113303A0 (en) * 1994-04-08 1995-07-31 Brigham & Womens Hospital Treatment of autoimmune disease using oral tolerization and/or type I interferon
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
BR9714434A (pt) * 1996-12-24 2000-05-02 Biogen Inc Formulações de interferon liquidas estáveis

Also Published As

Publication number Publication date
NZ336548A (en) 2001-09-28
JP2007204501A (ja) 2007-08-16
JP2012006979A (ja) 2012-01-12
HUP0000829A2 (en) 2000-07-28
EA002754B1 (ru) 2002-08-29
KR20000069664A (ko) 2000-11-25
DE69729880D1 (de) 2004-08-19
SK85899A3 (en) 2000-01-18
TR199901968T2 (xx) 1999-12-21
CA2275890C (en) 2011-11-01
SK284989B6 (sk) 2006-04-06
BG65171B1 (bg) 2007-05-31
EE200300127A (et) 2003-06-16
SI0948358T1 (en) 2005-04-30
CN1733296B (zh) 2010-05-26
HK1025040A1 (en) 2000-11-03
AU738362B2 (en) 2001-09-13
EE04223B1 (et) 2004-02-16
DE69729880T3 (de) 2012-05-10
EP0948358A1 (en) 1999-10-13
JP2001519770A (ja) 2001-10-23
KR101042660B1 (ko) 2011-06-20
CN1222315C (zh) 2005-10-12
PL193447B1 (pl) 2007-02-28
NO327844B1 (no) 2009-10-05
JP2011068694A (ja) 2011-04-07
JP4878664B2 (ja) 2012-02-15
BG103594A (en) 2000-04-28
JP5851695B2 (ja) 2016-02-03
PL334365A1 (en) 2000-02-28
KR20070052363A (ko) 2007-05-21
EE04266B1 (et) 2004-04-15
EA199900597A1 (ru) 2000-02-28
NO993121D0 (no) 1999-06-23
EP0948358B2 (en) 2011-11-23
HU224222B1 (hu) 2005-06-28
DK0948358T3 (da) 2004-11-08
BR9714434A (pt) 2000-05-02
AU5619198A (en) 1998-07-17
ES2224290T5 (es) 2012-03-12
IL130524A0 (en) 2000-06-01
BG109523A (en) 2007-05-31
WO1998028007A1 (en) 1998-07-02
PT948358E (pt) 2004-10-29
ES2224290T3 (es) 2005-03-01
CN1733296A (zh) 2006-02-15
HK1092048A1 (zh) 2007-02-02
ATE270899T1 (de) 2004-07-15
DK0948358T4 (da) 2012-03-19
IS5087A (is) 1999-06-21
CZ300636B6 (cs) 2009-07-08
CA2275890A1 (en) 1998-07-02
NZ512792A (en) 2002-11-26
MX337876B (es) 2016-03-22
EP0948358B1 (en) 2004-07-14
DE69729880T2 (de) 2005-07-07
SI0948358T2 (sl) 2012-03-30
IS2070B (is) 2005-12-15
CZ228299A3 (cs) 1999-12-15
JP2014098029A (ja) 2014-05-29
HUP0000829A3 (en) 2002-01-28
EE9900313A (et) 2000-04-17
NO993121L (no) 1999-08-24
CN1245434A (zh) 2000-02-23
IL130524A (en) 2005-08-31

Similar Documents

Publication Publication Date Title
BG65418B1 (bg) Кит за парентерално приложение на стабилни течни интерферонови състави
EP1633388B1 (en) Liquid stabilized interferon-beta formulations in coated pharmaceutical containers
EP1986612B1 (en) Stabilized composition of glucocerebrosidase
US9522174B2 (en) Stable liquid interferon beta formulations
EA010979B1 (ru) Стабилизированные жидкие препаративные формы интерферона
US20170360891A1 (en) Stable, Benzyl Alcohol-free Aqueous Solution Formulations Containing Alpha-type Interferon
WO2011161165A1 (en) Long-term storage of non-glycosylated recombinant human g-csf
HK1025040B (en) Stable liquid interferon formulations